Medscape is available in 5 Language Editions – Choose your Edition here.


Cylindroma Clinical Presentation

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Dirk M Elston, MD  more...
Updated: Feb 08, 2016


The solitary form usually begins in middle age or later as a slow-growing, rubbery nodule exhibiting no symptoms.

The dominantly inherited, multiple variety appears shortly after puberty as numerous, rounded nodules of various sizes ranging from several millimeters to larger than 6 cm. Lesions grow slowly, and additional lesions develop over time.

Loss of CYLD can be linked with development of salivary gland cancers.[13]

Brooke-Spiegler syndrome (BSS) associated with unilateral hearing loss has been reported.[14] BSS manifesting with pegged teeth has been reported.[15]



Except for BSS, pertinent findings are largely limited to the skin. Histologically similar tumors have been found in the breast, parotid glands, salivary glands, lacrimal gland of the eye, Bartholin glands, the brain, lungs, and kidneys. An interesting case of cylindroma was reported on the breast in 2013.[16]

Skin lesions associated with cylindromas

Solitary lesions are firm, rubbery nodules with pink, red, or sometimes blue coloring that range in size from a few millimeters to several centimeters.

The multiple form has numerous masses of pink, red, or blue nodules, sometimes resembling bunches of grapes or small tomatoes (sometimes called a tomato tumor).

Dermal cylindromas are noted, some which can be in the deep dermis.[17]

Skin distribution of cylindromas

The solitary form is typically found on the head and neck. The multiple form most commonly occurs on the head and neck but can also be seen on the trunk and the extremities.



The cause of sporadic, solitary cylindromas is largely unknown; however, genetic studies of sporadic cylindromas show loss of heterozygosity at and around the CYLD locus in a substantial number of cases, suggesting that this gene also plays a role in the development of sporadic tumors.

The tyrosine kinase pathway might be a treatment target in tumors with defective CYLD.[18]

Familial cylindromatosis is inherited in an autosomal dominant fashion, and the responsible gene, CYLD, is located on band 16q12-13. Tumors exhibit loss of heterozygosity, implicating the gene as a tumor suppressor gene. The precise biological function of the CYLD gene is yet to be elucidated. It has 4 functional motifs: CAP-GLY domains, proline-rich domains, metal-binding fingerlike domains, and regions with homology to UCH-catalytic domains. The CYLD gene consists of 20 exons; the first 3 are untranslated and the latter 17 are coding exons. Various mutations have been observed, such as frameshift, nonsense, or splice site mutations. Most mutations occur in 3'2/3rds of the C-terminal coding portion of the gene, in exons 9-20.

Contributor Information and Disclosures

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.


Anusuya Mokashi, MD, MS Resident Physician, Department of Radiology, Staten Island University Hospital

Disclosure: Nothing to disclose.

Julide Tok Celebi, MD Assistant Professor of Dermatology, Columbia University, College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, New York Presbyterian Medical Center

Julide Tok Celebi, MD is a member of the following medical societies: American Academy of Dermatology, American Association for Cancer Research, Society for Investigative Dermatology, Society for Melanoma Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Christen M Mowad, MD Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, Noah Worcester Dermatological Society, Pennsylvania Academy of Dermatology, American Academy of Dermatology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Abby S Van Voorhees, MD Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania

Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, Women's Dermatologic Society, National Psoriasis Foundation, American Medical Association, Phi Beta Kappa, Sigma Xi

Disclosure: Received honoraria from Amgen for consulting; Received honoraria from Abbott for consulting; Partner received salary from Merck for management position; Received honoraria from Abbott for speaking and teaching; Received honoraria from Amgen for review panel membership; Received honoraria from Centocor for consulting; Received honoraria from Leo for consulting; Received none from Merck for other.


Arnold R Oppenheim, MD Assistant Professor, Department of Internal Medicine, Division of Dermatology, Eastern Virginia School of Medicine

Arnold R Oppenheim, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Clinical Pathology

Disclosure: Nothing to disclose.

  1. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000 Jun. 25(2):160-5. [Medline].

  2. Bowen S, Gill M, Lee DA, et al. Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. J Invest Dermatol. 2005 May. 124(5):919-20. [Medline].

  3. Zhang G, Huang Y, Yan K, et al. Diverse phenotype of Brooke-Spiegler syndrome associated with a nonsense mutation in the CYLD tumor suppressor gene. Exp Dermatol. 2006 Dec. 15(12):966-70. [Medline].

  4. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A. 2007 May 22. 104(21):8869-74. [Medline].

  5. Massoumi R, Paus R. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays. 2007 Dec. 29(12):1203-14. [Medline].

  6. Fehr A, Kovács A, Löning T, Frierson H Jr, van den Oord J, Stenman G. The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol. 2011 Jul. 224(3):322-7. [Medline].

  7. Trufant J, Robinson M, Patel R. Brooke-Spiegler syndrome. Dermatol Online J. 2012 Dec 15. 18(12):16. [Medline].

  8. Grossmann P, Vanecek T, Steiner P, et al. Novel and Recurrent Germline and Somatic Mutations in a Cohort of 67 Patients From 48 Families With Brooke-Spiegler Syndrome Including the Phenotypic Variant of Multiple Familial Trichoepitheliomas and Correlation With the Histopathologic Findings in 379 Biopsy Specimens. Am J Dermatopathol. 2013 Feb. 35(1):34-44. [Medline].

  9. Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat. 2014 Jan 8. [Medline].

  10. Sellheyer K. Spiradenoma and cylindroma originate from the hair follicle bulge and not from the eccrine sweat gland: an immunohistochemical study with CD200 and other stem cell markers. J Cutan Pathol. 2014 Oct 29. [Medline].

  11. Pinho AC, Gouveia MJ, Gameiro AR, Cardoso JC, Gonçalo MM. Brooke-Spiegler Syndrome - an underrecognized cause of multiple familial scalp tumors: report of a new germline mutation. J Dermatol Case Rep. 2015 Sep 30. 9 (3):67-70. [Medline].

  12. Chen M, Liu H, Fu X, Yu Y, Yu G, Tian H, et al. Brooke-Spiegler syndrome associated with cylindroma, trichoepithelioma and eccrine spiradenoma. Int J Dermatol. 2013 Dec. 52:1602-4.

  13. Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H. Loss of CYLD might be associated with development of salivary gland tumors. Oncol Rep. 2008 Jun. 19(6):1421-7. [Medline].

  14. Parren LJ, Bauer B, Hamm H, Frank J. Brooke-Spiegler syndrome complicated by unilateral hearing loss. Int J Dermatol. 2008 Nov. 47 Suppl 1:56-9. [Medline].

  15. Carlson RM, Haddad L, Pui JC. Brooke-Spiegler syndrome with associated pegged teeth. Cutis. 2008 Nov. 82(5):345-9. [Medline].

  16. Aggarwal R, Gupta O, Yadav YK, Dogra S. Cylindroma of the breast: a rare case report. Int J Trichology. 5(2). 2013 Apr:83-5. [Medline].

  17. Singh DD, Naujoks C, Depprich R, Schulte KW, Jankowiak F, Kübler NR, et al. Cylindroma of head and neck: Review of the literature and report of two rare cases. J Craniomaxillofac Surg. 2012 Dec 20. [Medline].

  18. Rajan N, Elliott R, Clewes O, et al. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene. 2011 May 9. [Medline].

  19. Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol. 2012 Apr 18. [Medline].

  20. Cohen YK, Elpern DJ. Dermatoscopic pattern of a cylindroma. Dermatol Pract Concept. 2014 Jan 31. 4(1):67-8. [Medline].

  21. Ishihara M, Mehregan DR, Hashimoto K, et al. Staining of eccrine and apocrine neoplasms and metastatic adenocarcinoma with IKH-4, a monoclonal antibody specific for the eccrine gland. J Cutan Pathol. 1998 Feb. 25(2):100-5. [Medline].

  22. Fusco N, Colombo PE, Martelotto LG, De Filippo MR, Piscuoglio S, Ng CK, et al. Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology. 2016 Jan. 68 (2):262-271. [Medline].

  23. Rallan D, Harland CC. Brooke-Spiegler syndrome: treatment with laser ablation. Clin Exp Dermatol. 2005 Jul. 30(4):355-7. [Medline].

  24. Retamar RA, Stengel F, Saadi ME, et al. Brooke-Spiegler syndrome - report of four families: treatment with CO2 laser. Int J Dermatol. 2007 Jun. 46(6):583-6. [Medline].

  25. Kacerovska D, Szepe P, Vanecek T, et al. Spiradenocylindroma-like basaloid carcinoma of the anus and rectum: case report, including HPV studies and analysis of the CYLD gene mutations. Am J Dermatopathol. 2008 Oct. 30(5):472-6. [Medline].

  26. Bansal C, Batra M, Lal N, Srivastava AN. Solitary cylindroma with malignant transformation. Indian J Dermatol. 2012 Mar. 57(2):141-3. [Medline]. [Full Text].

  27. Tripathy SM, Somu TN, Sundaram M, Sadhiya S. Malignant Cylindroma of Post Aural Region Involving the Temporal Bone. J Clin Diagn Res. 2015 Jul. 9 (7):MD01-2. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.